semaglutide and hfpef In patients with heart failure with preserved ejection fraction obesity, but without type 2 diabetes, treatment has led to larger reductions in heart failure–related symptoms and physical limitations and greater STEP-HFpEF DM Trial Hints at
Description
Key obligations for drug manufacturers include: Thorough Testing : Conducting comprehensive pre-market testing to identify possible side effects
Epub 2011 Apr 8
Do not share your injection pen with others, even if the needle is changed, as this carries a risk of infection
The question of which intervention is better, Wegovy or bariatric surgery, doesnt have a straightforward answer
No regulatory guidance yet defines what biosimilarity means for an ADC like Kadcyla (ado-trastuzumab emtansine), where the drug-to-antibody ratio, linker chemistry, and released drug identity are all potential similarity endpoints in addition to the standard antibody characterization package
Diabetes Care 2013;36(7):18771883
